NYSE: HLV
₹142.50 ▲ +2.4%
Delivering Long-Term Shareholder Value.
Helvica Pharma is positioned for sustainable growth through robust R&D pipelines and strategic global market expansion.
Q3 2023 Highlights
Total Revenue
₹12.4B
+8.2% YoY
Net Income
₹3.1B
+11.5% YoY
R&D Expense
₹2.5B
+5.0% YoY